Pravastatin
Highest phase reached
Approved
Drug type
Small molecule
First approval year
1991
- First approval year
- 1991
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Pravastatin
- Molecular weight
- 424.53
- Structure (SMILES)
- CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(=O)O)[C@H]21
- c10aa03
- C10AA03
- pravastatin
- Pravastatin
- PRAVASTATIN [EMA EPAR]
- pravastatin [INN]
- PRAVASTATIN [VANDF]
- Pravastatin [WHO-DD]
- Pravastatin 20 mg oral tablet (ages <13 years)
- pravastatin 20 mg oral tablet ages 13 years
- pravastatin ema epar
- pravastatin inn
- pravastatin vandf
- pravastatin who dd
- pravastatina
- Pravastatina
- pravastatine
- Pravastatine
- pravator
- Pravator
- ATC classification codes
- C10AA03
Sources for recorded values
- CAS registry numbers
- 81093-37-0
- ChEMBL ID
- CHEMBL1144
- InChIKey
- TUZYXOIXSAXUGO-PZAWKZKUSA-N
- PubChem compound IDs
- 54687
- RxNorm IDs (RxCUI)
- 42463
- FDA ingredient codes (UNII)
- KXO2KT9N0G
- Applicant
- BRISTOL MYERS SQUIBB
- Approval date
- 31 Oct 1991
- Application number
- NDA019898
- First in class
- No
- Orphan designation
- No
- Availability
- Prescription only
- United States (FDA)
- Approved
- Pharmacology name
- pravastatin
- Type
- Synthetic organic
- Drug name stem
- -stat-
- Approval recorded by Guide to Pharmacology
- Yes
Administration routes
- Oral
- Action
- Binding
- Action type
- Binding
- Target
- OATP1B1
- Gene symbol
- SLCO1B1
- Protein identifier
- Q9Y6L6
- Action
- Competitive
- Action type
- COMPETITIVE
- Target
- hydroxymethylglutaryl-CoA reductase
- Gene symbol
- HMGCR
- Protein identifier
- P04035
- Median affinity
- 5.86
- Affinity units
- pIC50
- Primary target
- Yes
- Action
- Competitive
- Action type
- COMPETITIVE
- Target
- hydroxymethylglutaryl-CoA reductase
- Gene symbol
- HMGCR
- Protein identifier
- P04035
- Median affinity
- 7.52
- Affinity units
- pIC50
- Primary target
- Yes
- Action
- Competitive
- Action type
- COMPETITIVE
- Target
- hydroxymethylglutaryl-CoA reductase
- Gene symbol
- HMGCR
- Protein identifier
- P04035
- Median affinity
- 6.99
- Affinity units
- pKi
- Primary target
- Yes
Open Targets mechanisms
- Mechanism
- HMG-CoA reductase inhibitor
- Action type
- Inhibitor
- Target
- 3-hydroxy-3-methylglutaryl-coenzyme A reductase
DrugCentral mechanisms
- Action type
- Inhibitor
- Gene symbol
- HMGCR
- Protein identifier
- P04035
- Organism
- Homo sapiens
- Target development level
- Clinical
- Condition
- Carcinoma, Hepatocellular
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000182
- Subject identifier
- D006528
- Condition
- Carcinoma
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000313
- Subject identifier
- D002277
- Condition
- Cardiomyopathies
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000318
- Subject identifier
- D009202
- Condition
- Cardiovascular Diseases
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000319
- Subject identifier
- D002318
- Condition
- Diabetes Mellitus
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000400
- Subject identifier
- D003920
- Condition
- Hypertension
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000537
- Subject identifier
- D006973
- Condition
- Leukemia
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000565
- Subject identifier
- D007938
- Condition
- Myocardial Infarction
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000612
- Subject identifier
- D009203
- Condition
- Pre-Eclampsia
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000668
- Subject identifier
- D011225
- Condition
- Arthritis, Rheumatoid
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000685
- Subject identifier
- D001172
- Condition
- HIV Infections
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000764
- Subject identifier
- D015658
- Condition
- Pneumonia
- Highest recorded phase
- 0.5
- Condition identifier
- EFO:0003106
- Subject identifier
- D011014
- Condition
- Heart Failure
- Highest recorded phase
- 3
- Condition identifier
- EFO:0003144
- Subject identifier
- D006333
- Condition
- Renal Insufficiency, Chronic
- Highest recorded phase
- 3
- Condition identifier
- EFO:0003884
- Subject identifier
- D051436
- Condition
- Multiple Sclerosis, Relapsing-Remitting
- Highest recorded phase
- 3
- Condition identifier
- EFO:0003929
- Subject identifier
- D020529
- Condition
- Mucocutaneous Lymph Node Syndrome
- Highest recorded phase
- 2
- Condition identifier
- EFO:0004246
- Subject identifier
- D009080
- Condition
- Fibrosis
- Highest recorded phase
- 2
- Condition identifier
- EFO:0006890
- Subject identifier
- D005355
- Condition
- Tuberculosis, Pulmonary
- Highest recorded phase
- 2
- Condition identifier
- EFO:1000049
- Subject identifier
- D014397
- Condition
- Myocardial Ischemia
- Highest recorded phase
- 3
- Condition identifier
- EFO:1001375
- Subject identifier
- D017202
- Condition
- Polycystic Kidney, Autosomal Dominant
- Highest recorded phase
- 3
- Condition identifier
- EFO:1001496
- Subject identifier
- D016891
- Condition
- Acute Kidney Injury
- Highest recorded phase
- 1
- Condition identifier
- HP:0001919
- Subject identifier
- D058186
- Condition
- Ischemic Stroke
- Highest recorded phase
- 3
- Condition identifier
- HP:0002140
- Subject identifier
- D000083242
- Condition
- Hypercholesterolemia
- Highest recorded phase
- 3
- Condition identifier
- HP:0003124
- Subject identifier
- D006937
- Condition
- Breast Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0007254
- Subject identifier
- D001943
- Condition
- Lupus Erythematosus, Systemic
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0007915
- Subject identifier
- D008180
And 7 more, listed on the interactive page.
- Condition identifier
- EFO_0000182
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000195
- Condition identifier
- EFO_0000195
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000313
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000319
- Condition identifier
- EFO_0000384
- Condition identifier
- EFO_0000565
- Highest recorded phase
- 1
- Condition identifier
- EFO_0000668
- Highest recorded phase
- 3
- Condition identifier
- EFO_0001065
- Condition identifier
- EFO_0003106
- Condition identifier
- EFO_0003777
- Condition identifier
- EFO_0003884
- Highest recorded phase
- 1
- Condition identifier
- EFO_0003929
- Highest recorded phase
- 3
- Condition identifier
- EFO_0004246
- Highest recorded phase
- 2
- Condition identifier
- EFO_0006890
- Highest recorded phase
- 2
- Condition identifier
- EFO_0803536
- Highest recorded phase
- 3
- Condition identifier
- EFO_1001461
- Highest recorded phase
- 2
- Condition identifier
- EFO_1001496
- Highest recorded phase
- 3
- Condition identifier
- HP_0000822
- Highest recorded phase
- 1
- Condition identifier
- HP_0001297
- Highest recorded phase
- 3
- Condition identifier
- HP_0002140
- Highest recorded phase
- 3
- Condition identifier
- HP_0003124
- Highest recorded phase
- 3
- Condition identifier
- HP_0012664
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0001336
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0002525
And 33 more, listed on the interactive page.
- Event
- blood cholesterol increased
- Reports
- 19
- Reporting signal score
- 21.4762
- Event
- blood creatine phosphokinase increased
- Reports
- 3,120
- Reporting signal score
- 5,793.48
- Event
- cholestatic liver injury
- Reports
- 8
- Reporting signal score
- 21.6408
- Event
- chromaturia
- Reports
- 15
- Reporting signal score
- 20.91
- Event
- drug hypersensitivity
- Reports
- 66
- Reporting signal score
- 30.8176
- Event
- drug interaction
- Reports
- 3,622
- Reporting signal score
- 2,583.58
- Event
- immune-mediated myositis
- Reports
- 476
- Reporting signal score
- 1,519.04
- Event
- immune-mediated necrotising myopathy
- Reports
- 365
- Reporting signal score
- 1,182.4
- Event
- liver function test abnormal
- Reports
- 983
- Reporting signal score
- 872.711
- Event
- monoclonal b-cell lymphocytosis
- Reports
- 6
- Reporting signal score
- 31.8073
- Event
- muscle rupture
- Reports
- 18
- Reporting signal score
- 57.7606
- Event
- muscular weakness
- Reports
- 2,037
- Reporting signal score
- 1,790.42
- Event
- myalgia
- Reports
- 6,906
- Reporting signal score
- 10,685.1
- Event
- myopathy
- Reports
- 1,546
- Reporting signal score
- 3,852.48
- Event
- myositis
- Reports
- 734
- Reporting signal score
- 1,328.7
- Event
- polymyositis
- Reports
- 8
- Reporting signal score
- 21.2083
- Event
- renal failure acute
- Reports
- 1,470
- Reporting signal score
- 1,204.36
- Event
- rhabdomyolysis
- Reports
- 6,532
- Reporting signal score
- 15,491.3
- Event
- tendon rupture
- Reports
- 20
- Reporting signal score
- 41.5892
- NCT00000461
- NCT00000542
- NCT00132717
- NCT00532311
- NCT00654537
- NCT03510715
- NCT00738972
- NCT00005010
- NCT00571194
- NCT00039663
- NCT00665717
- NCT04425902
- NCT00054938
- NCT00107523
- NCT02484261
- NCT00200655
- NCT00214604
- NCT00221104
- NCT00361530
- NCT00361699
- NCT00305201
- NCT00362206
- NCT00688896
- NCT00456365
- NCT04284657
And 25 more, listed on the interactive page.
- Dose
- 40-80mg
- Route
- Oral
- How often
- Once daily
Conditions of use
- Take with or without food
- Hydrogen bond acceptors
- 6
- Hydrogen bond donors
- 4
- Polar surface area
- 124.29
- Calculated partition coefficient (ALogP)
- 2.44
- Calculated partition coefficient (XLogP)
- 1.6
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 10
- Heavy atoms
- 30
- Molecular formula
- C23H36O7
- Monoisotopic mass
- 424.24610348
- Natural product
- Yes
- Recorded assays
- 1,791
- Active assays
- 35
- Confirmatory
- Other
- Anticholesteremic Agents
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
Distribution coefficient (LogD)
- Median
- -0.4
- Mean
- -0.4
- Minimum
- -0.4
- Maximum
- -0.4
- Unit
- unitless
- Assays
- 1
- Standard deviation
- 0
- Summary method
- median
- Censored results excluded
- 0
- Other units excluded
- 0
- Unknown units excluded
- 0
Measurement types
- LogD
Liver toxicity assay
- Median
- 17
- Mean
- 21
- Minimum
- 17
- Maximum
- 29
- Unit
- nM
- Assays
- 3
- Standard deviation
- 6.9282
- Summary method
- median
- Censored results excluded
- 0
- Other units excluded
- 0
- Unknown units excluded
- 0
Measurement types
- IC50
Oral bioavailability
- Median
- 17
- Mean
- 17
- Minimum
- 17
- Maximum
- 17
- Unit
- %
- Assays
- 1
- Standard deviation
- 0
- Summary method
- median
- Censored results excluded
- 0
- Other units excluded
- 0
- Unknown units excluded
- 0
Measurement types
- F
Related records
Trials (132)
- A 12 Week Study of MK0653A in Patients Who Have Been Hospitalized for a Possible Heart Problem (0653A-808)
- A 12-Week Study Comparing Pitavastatin 4 mg vs. Pravastatin 40 mg in HIV-Infected Subjects
- A Clinical Trial to Evaluate MK-4208/Embibatinib in Healthy Adult Participants (MK-4208-001/Embibatinib-1014)
- A Drug-Drug Interaction Study Between AZD1981 and Pravastatin to Study the Effect of AZD1981 on the Kinetics of Pravastatin
- A Study Comparing the Mechanisms of Action of Lifibrol and Pravastatin
- A Study of Evacetrapib in Japanese and Non-Japanese Participants
- A Study of the PK Interaction of CXA-10 With Pravastatin and Vytorin® in Healthy Males
- A Study of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With Progeria
- A Study to Assess the Effect of RO4607381 in Patients With Relatively Low Levels of High Density Lipoprotein-Cholesterol (HDL-C)
- A Study to Determine the Effect of WelChol Tablets on Cholesterol in Patients Who Have Been Taking Pravastatin for at Least 4 Weeks.
- A Study to Evaluate Daily Pravastatin, Fenofibrate or Pravafen in the Treatment of Combined Hyperlipidemia
- A Study to Evaluate the Drug-drug Interaction Potential of BMS-986196 in Healthy Participants
- A Trial Comparing the Effect of Pravastatin and Rosuvastatin on Atherosclerosis Progression Measured by Carotid Intima Media Thickness in Patients With Coronary Artery Disease After Biolimus Eluting Stent (Nobori®) Implantation: CPR IMT
- Additive Effects of Pravastatin and Valsartan
- Aggressive Treatment of Metabolic Syndrome in Patients Receiving Clozapine for Schizophrenia
- An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia
- An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia
- An Observational Study Investigating the Effectiveness of Pravastatin on Renal Function in Korean Dyslipidemic Patients With Type 2 Diabetes
- Anti-Oxidant Therapy In Chronic Renal Insufficiency (ATIC) Study
- Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
Approved for (1)
In development for (43)
- Acute kidney injury Phase 1
- Acute myeloid leukemia Phase 1
- Autosomal dominant polycystic kidney disease Phase 3
- Breast cancer Phase 2
- Breast fibrosis Phase 2
- Carcinoma Phase 2
- Cardiomyopathy Phase 2
- Chronic kidney disease Phase 3
- Coronary artery disorder Phase 3
- Coronary atherosclerosis Phase 2
- Diabetes mellitus Phase 3
- Familial hyperlipidemia Phase 1
- Fetal growth restriction Phase 2
- Heart failure Phase 3
- Hepatocellular carcinoma Phase 3
- Hermansky-Pudlak syndrome Phase 1
- HIV infectious disease Phase 1
- Hutchinson-Gilford progeria syndrome Phase 2
- Hyperlipidemia Phase 3
- Hyperlipidemia, familial combined, LPL related Phase 3